RecruitingNot Applicable

Probiotics to Actively Counter Ventilator Associated Pneumonia (PROACT)

Belgium, Italy186 participantsStarted 2023-12-13

Plain-language summary

PROACT study aims to resolve uncertainties to influence actual practice guidelines or public health policing regarding VAP prevention in ICU by using probiotics administration. Multi-trauma patients with a head injury OR stroke or brain haemorrhage patients without any sign of aspiration and lung infection will be enrolled and randomized to either placebo or probiotic treatment to assess if VAP and mortality can be reduced in the interventional group.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material \[mechanical or bioprosthetic cardiac valves\]
✕. previous or current endocarditis
✕. permanent endovascular devices (e.g., endovascular grafts \[e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids\] inferior vena cava filters, dialysis vascular grafts
✕. tunnelled (not short-term) hemodialysis catheters
✕. pacemakers or defibrillators

What they're measuring

Vap Incidence

Timeframe: 45 days

Trial details

NCT IDNCT06092554

SponsorUniversity of Bari

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-15

Contact for this trial

Alberto Corriero, MD

+393280072443 alberto.corriero@gmail.com

View on ClinicalTrials.gov More Ventilator Associated Pneumonia trials